FDA announcement or approval records

Amgen to Launch Biosimilar of Regeneron's Eylea After Tuesday Court Ruling

Oct 22, 2024, 07:13 PM

Amgen has announced the launch of its biosimilar version of Regeneron's blockbuster eye care drug Eylea. This follows a ruling by the U.S. appeals court in favor of Amgen on Tuesday, which denied Regeneron's motion for a preliminary injunction to block the biosimilar. An Amgen spokesperson said this decision marks a significant development in the pharmaceutical industry, particularly in the market for eye care treatments.